Exscientia and Recursion Merge to Revolutionize Drug Discovery

Exscientia Plc (EXAI) has released an update.

Exscientia Plc merges with Recursion to form a powerful AI-driven drug discovery platform, marking a significant step in the industrialization of drug development. This strategic move results in Exscientia becoming a wholly owned subsidiary of Recursion, enhancing their capabilities with over 10 clinical and preclinical programs and potential milestone payments exceeding $20 billion. The merger aims to accelerate drug discovery processes, reduce costs, and introduce innovative treatments faster than traditional methods.

For further insights into EXAI stock, check out TipRanks’ Stock Analysis page.